Latest Trials Latest NewsFAQ

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma

Phase 1

Completed

Conditions: Neuroblastoma

Interventions: Biological: monoclonal antibody 3F8
Biological: sargramostim

First Posted Date: 2007-03-22

Last Posted Date: 2013-10-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 32

Registration Number: NCT00450307

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma

Phase 1

Completed

Conditions: Neuroblastoma

Interventions: Biological: bevacizumab
Biological: filgrastim
Procedure: autologous hematopoietic stem cell transplantation
Radiation: iodine I 131 monoclonal antibody 3F8

First Posted Date: 2007-03-22

Last Posted Date: 2015-09-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 25

Registration Number: NCT00450827

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Phase 2

Completed

Conditions: Neuroblastoma
Brain and Central Nervous System Tumors
Metastatic Cancer
Retinoblastoma
Sarcoma
Small Intestine Cancer
Intraocular Melanoma
Ovarian Cancer
Lung Cancer
Melanoma (Skin)

Interventions: Genetic: DNA analysis
Other: immunologic technique
Other: pharmacological study
Radiation: iodine I 131 monoclonal antibody 3F8
Radiation: 131I-3F8

First Posted Date: 2007-03-09

Last Posted Date: 2024-04-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 78

Registration Number: NCT00445965

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

Not Applicable

Conditions: Breast Cancer

First Posted Date: 2007-02-19

Last Posted Date: 2014-01-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 75

Registration Number: NCT00436709

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Lymphoma
Leukemia

Interventions: Biological: anti-thymocyte globulin
Biological: filgrastim
Biological: graft-versus-tumor induction therapy
Biological: rituximab
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Radiation: total-body irradiation

First Posted Date: 2007-01-23

Last Posted Date: 2017-10-31

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 61

Registration Number: NCT00425802

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

Phase 1

Completed

Conditions: Graft Versus Host Disease
Leukemia
Myelodysplastic Syndromes

Interventions: Biological: filgrastim
Drug: clofarabine
Drug: melphalan
Drug: mycophenolate mofetil
Drug: tacrolimus
Drug: thiotepa
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2007-01-18

Last Posted Date: 2022-12-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 38

Registration Number: NCT00423514

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Biological: bevacizumab
Drug: cisplatin
Procedure: conventional surgery
Radiation: intensity-modulated radiation therapy

First Posted Date: 2007-01-18

Last Posted Date: 2017-08-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 44

Registration Number: NCT00423930

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin

Phase 1

Completed

Conditions: Ovarian Cancer
Testicular Germ Cell Tumor
Brain and Central Nervous System Tumors
Teratoma
Extragonadal Germ Cell Tumor

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: ifosfamide
Drug: paclitaxel
Procedure: autologous hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2007-01-18

Last Posted Date: 2016-05-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 26

Registration Number: NCT00423852

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: cisplatin
Drug: everolimus
Genetic: gene expression analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Other: pharmacological study
Procedure: biopsy

First Posted Date: 2007-01-18

Last Posted Date: 2015-05-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT00423865

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma

Phase 1

Completed

Conditions: Renal Cell Carcinoma
Kidney Cancer

Interventions: Drug: RAD001, Sunitinib

First Posted Date: 2007-01-15

Last Posted Date: 2010-02-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT00422344

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy